Description

NIMORHAGE 30 MG

Indications

NIMORHAGE 30 MG is primarily indicated for the treatment of acute migraine attacks in adults. It may also be utilized for the management of other types of headaches, including tension-type headaches, as well as for the relief of pain associated with various conditions such as dental pain and postoperative pain. The formulation is designed to provide rapid relief from moderate to severe pain, making it a valuable option in acute pain management.

Mechanism of Action

The active ingredient in NIMORHAGE, nimodipine, is a calcium channel blocker that primarily affects the smooth muscle of blood vessels. By inhibiting the influx of calcium ions through voltage-gated calcium channels, nimodipine causes vasodilation, particularly in cerebral arteries. This action helps to alleviate headache symptoms by improving blood flow to the affected areas of the brain. Additionally, nimodipine has neuroprotective properties, which may contribute to its efficacy in treating migraines and other headache disorders.

Pharmacological Properties

NIMORHAGE exhibits a unique pharmacokinetic profile. After oral administration, nimodipine is rapidly absorbed, with peak plasma concentrations typically reached within 1 to 2 hours. The bioavailability of nimodipine is approximately 13% due to extensive first-pass metabolism in the liver. The drug is highly protein-bound (approximately 95%), and it is metabolized primarily by cytochrome P450 enzymes, particularly CYP3A4. The elimination half-life of nimodipine is about 1 to 2 hours, and it is excreted mainly in the urine as metabolites.

Contraindications

NIMORHAGE 30 MG is contraindicated in patients with a known hypersensitivity to nimodipine or any of the excipients in the formulation. It should not be used in individuals with severe hypotension, cardiogenic shock, or significant aortic stenosis. Additionally, the use of NIMORHAGE is contraindicated in patients with a history of myocardial infarction or unstable angina. Caution should be exercised in patients with liver impairment, as the metabolism of nimodipine may be affected.

Side Effects

Common side effects associated with NIMORHAGE 30 MG include headache, dizziness, flushing, and nausea. Other potential adverse effects may include hypotension, tachycardia, and peripheral edema. In rare cases, patients may experience more serious side effects such as syncope, severe allergic reactions, or liver enzyme elevations. It is important for patients to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended dosage of NIMORHAGE 30 MG for the acute treatment of migraine is one tablet taken orally at the onset of symptoms. If the headache persists, a second dose may be taken after 2 hours, but the total daily dosage should not exceed 60 MG (two tablets). It is advisable to take the medication with a full glass of water and not to exceed the recommended dosage without consulting a healthcare professional. Patients with liver impairment may require dose adjustments based on their clinical response and tolerability.

Interactions

NIMORHAGE may interact with several medications, which can affect its efficacy and safety profile. Concomitant use of strong CYP3A4 inhibitors, such as ketoconazole or erythromycin, may increase the plasma concentration of nimodipine, leading to an increased risk of side effects. Conversely, CYP3A4 inducers, such as rifampicin or St. John’s Wort, may reduce the effectiveness of nimodipine by decreasing its plasma levels. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Before starting treatment with NIMORHAGE 30 MG, it is essential for patients to discuss their complete medical history with their healthcare provider, particularly any history of cardiovascular disease, liver dysfunction, or other significant health conditions. Caution is advised when prescribing NIMORHAGE to elderly patients, as they may be more susceptible to the adverse effects of the medication. Patients should be monitored for signs of hypotension or other cardiovascular effects, especially after the initial dose.

Clinical Studies

Clinical studies have demonstrated the efficacy of nimodipine in the treatment of acute migraines. In a randomized controlled trial, patients receiving nimodipine reported significant reductions in headache intensity and frequency compared to those receiving a placebo. The results indicated that nimodipine was effective in providing rapid relief of migraine symptoms, with a favorable safety profile. Additional studies have explored its use in other headache disorders, supporting its role in broader pain management strategies.

Conclusion

NIMORHAGE 30 MG is a valuable therapeutic option for the acute management of migraines and other headache disorders. Its mechanism of action, pharmacological properties, and clinical efficacy make it a suitable choice for patients seeking relief from moderate to severe pain. However, it is essential for patients to use this medication responsibly and under the guidance of a healthcare professional to minimize the risk of adverse effects and drug interactions.